Antifungals Global Market Report 2026

Antifungal drugs are medications used to identify and eliminate fungal pathogens. These pathogens tend to thrive in the body under unhygienic and unclean conditions. These drugs, also called antimycotic medications, are employed to treat and prevent mycoses such as athlete's foot, ringworm, candidiasis (thrush), and severe systemic infections like cryptococcal meningitis, among others.

The primary categories of antifungal drugs include echinocandins, azoles, polyenes, and allylamines. Echinocandins represent a newer class of antifungal agents that function by blocking the synthesis of 1,3-D-glucan, an essential component of the fungal cell wall, in a manner that specifically targets fungi. The available routes of administration comprise oral, parenteral, and topical methods, addressing various therapeutic applications such as aspergillosis, dermatophytosis, candidiasis, and more. The different user sectors encompass hospitals and clinics, dermatology centers, and other end-users.

Tariffs have raised the cost of imported antifungal APIs and key synthesis intermediates used in pharmaceutical manufacturing. These impacts are most pronounced in Europe and Asia Pacific, where many producers depend on cross border sourcing for antifungal drug inputs. Rising tariff related expenses have placed pressure on production costs and pricing strategies across hospital and retail antifungal therapies. This has influenced procurement planning and supply availability in several markets. However, tariffs are also encouraging domestic pharmaceutical production, local API manufacturing, and stronger regional supply chains over the long term.

The antifungals market research report is one of a series of new reports from The Business Research Company that provides antifungals market statistics, including antifungals industry global market size, regional shares, competitors with a antifungals market share, detailed antifungals market segments, market trends and opportunities, and any further data you may need to thrive in the antifungals industry. This antifungals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antifungals market size has grown strongly in recent years. It will grow from $29.6 billion in 2025 to $31.98 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increase in hospital-acquired infections, widespread use of azoles, rising immunosuppressed population, established antifungal therapies, global burden of mycoses.

The antifungals market size is expected to see strong growth in the next few years. It will grow to $44.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growth in systemic fungal infections, antifungal resistance concerns, demand for safer therapies, expansion of hospital care, increased diagnosis rates. Major trends in the forecast period include rising prevalence of fungal infections, growing demand for broad-spectrum antifungals, expansion of topical antifungal treatments, increased use in immunocompromised patients, development of novel antifungal drug classes.

The rising prevalence of fungal infections is anticipated to drive the expansion of the antifungals market in the coming years. Fungal infections are illnesses caused by the invasion and growth of fungi in or on the body, affecting various areas such as the skin, nails, lungs, and mucous membranes. The increasing occurrence of fungal infections is attributed to climate change, which creates favorable conditions for fungi to spread and adapt to higher temperatures, thereby raising human exposure and infection risks. Antifungals are essential in managing fungal diseases by inhibiting fungal growth and reproduction, either through disrupting their cell wall or membrane, blocking critical enzymatic processes, or interfering with the synthesis of vital components, thus reducing fungal load, alleviating symptoms, and preventing further spread within the body. For example, in May 2025, the UK Health Security Agency, a UK government department, reported that bloodstream infections caused by yeast rose by 4% in 2024 compared with 2023, increasing from 2,170 to 2,247 cases. Consequently, the growing incidence of fungal infections is fueling the antifungals market's growth.

The growth of the antifungals market is expected to be driven by the expansion of healthcare infrastructure in the coming years. Healthcare infrastructure refers to the physical and organizational structures, facilities, and systems that enable the delivery of healthcare services. The rise in healthcare infrastructure is mainly attributed to increased government support and investments through various policies and incentives, which encourage the development of healthcare facilities. Healthcare infrastructure includes the essential facilities, systems, and resources required to provide healthcare services for the effective management of fungal infections. For example, in May 2024, according to Baker McKenzie, an Australia-based law firm, the Australian government allocated $1.82 billion (AUD 2.8 billion) to strengthen Medicare, building on the $3.95 billion (AUD 6.1 billion) Medicare investment in the 2023-24 Federal Budget, along with USD 91.48 million (AUD 141.1 million) for medical research and services for people with chronic conditions such as bowel and skin cancer, diabetes, and dementia. Therefore, the growth of healthcare infrastructure is driving the expansion of the antifungals market in the foreseeable future.

Major companies in the antifungals market are concentrating on product innovation and formulation, such as long-acting echinocandin therapies, to enhance patient adherence, decrease dosing frequency, and meet unmet clinical needs in invasive fungal infections. By prolonging the half-life and altering pharmacokinetics, these next-generation antifungals provide effective fungal suppression with more convenient administration schedules. For example, in March 2023, Cidara Therapeutics, a US-based biotechnology firm, together with Melinta Therapeutics (U.S.), announced FDA approval for REZZAYO (rezafungin for injection) for treating candidemia and invasive candidiasis. Rezafungin is a once-weekly echinocandin, demonstrating non-inferior efficacy compared to daily caspofungin in clinical trials (ReSTORE Phase 3), while maintaining a similar safety profile. The extended dosing capability of REZZAYO addresses a significant gap in antifungal therapy, supporting treatment continuity and reducing hospital burden in acute-care environments.

Major companies operating in the antifungals market are Pfizer Inc., Novartis International AG, Merck & Co. Inc., Bayer AG, Abbott Laboratories, Sanofi S.A., Kramer Laboratories Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Basilea Pharmaceutica AG, Sigma-Aldrich, Astellas Pharma Inc., Janssen Pharmaceutica NV, Zydus Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Scynexis Inc., Mayne Pharma Inc., Cosmo Pharmaceuticals NV, Leadiant Biosciences Inc, Glenmark Pharmaceuticals Limited, Cidara Therapeutics, MATINAS BIOPHARMA, Mylan N.V., Perrigo Company plc, Wockhardt Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd, Torrent Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Mayne Pharma Group Limited, Fresenius Kabi AG, Baxter International Inc., Akorn Operating Company LLC, Amphastar Pharmaceuticals Inc., Mylan Institutional LLC, West-Ward Pharmaceuticals Corp., Gland Pharma Limited, Aurobindo Pharma Limited

North America was the largest region in the drugs for antifungals market in 2025. The Middle East is expected to be the fastest-growing region in the antifungals market. The regions covered in the antifungals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antifungals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antifungal market consists of sales of clotrimazole, miconazole, and ketoconazole. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antifungals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses antifungals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antifungals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antifungals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Echinocandins; Azoles; Polyenes; Allylamines
• 2) By Route of Administration: Oral; Parenteral; Topical
• 3) By End users: Hospitals & Clinics; Dermatology clinics; Other Users
• Subsegments:
• 1) By Echinocandins: Caspofungin; Micafungin; Anidulafungin
• 2) By Azoles: Fluconazole; Itraconazole; Voriconazole; Posaconazole; Ketoconazole
• 3) By Polyenes: Amphotericin B; Nystatin
• 4) By Allylamines: Terbinafine; Naftifine
• Companies Mentioned: Pfizer Inc.; Novartis International AG; Merck & Co. Inc.; Bayer AG; Abbott Laboratories; Sanofi S.A.; Kramer Laboratories Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; Basilea Pharmaceutica AG; Sigma-Aldrich; Astellas Pharma Inc.; Janssen Pharmaceutica NV; Zydus Cadila Healthcare Ltd.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Scynexis Inc.; Mayne Pharma Inc.; Cosmo Pharmaceuticals NV; Leadiant Biosciences Inc; Glenmark Pharmaceuticals Limited; Cidara Therapeutics; MATINAS BIOPHARMA; Mylan N.V.; Perrigo Company plc; Wockhardt Ltd.; Lupin Limited; Dr. Reddy's Laboratories Ltd; Torrent Pharmaceuticals Ltd.; Hikma Pharmaceuticals PLC; Mayne Pharma Group Limited; Fresenius Kabi AG; Baxter International Inc.; Akorn Operating Company LLC; Amphastar Pharmaceuticals Inc.; Mylan Institutional LLC; West-Ward Pharmaceuticals Corp.; Gland Pharma Limited; Aurobindo Pharma Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.